|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, July 03, 2015 ) This report provides comprehensive information on the current therapeutic developmental pipeline of Ironwood Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.
Inquire more about this Report at http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=393985 . (This is a premium report price at US$1500 for a single user PDF license)
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
Scope:
• The report reviews current pipeline of Ironwood Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects
• The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
• The report summarizes all the dormant and discontinued pipeline projects
• Latest news and deals relating to the Ironwood Pharmaceuticals, Inc.'s pipeline products
• Latest company statement
• Special feature on out-licensed and partnered product portfolio
Inquire for discount on this report at http://www.rnrmarketresearch.com/contacts/discount?rname=393985 . (This is a premium report price at US$1500 for a single user PDF license)
Reasons to Buy:
• Assess the growth potential of Ironwood Pharmaceuticals, Inc. in its therapy areas of focus
• Identify new drug targets and therapeutic classes in the Ironwood Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
• Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
• Develop strategic initiatives by understanding the focus areas of Ironwood Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Plan mergers and acquisitions effectively by identifying the most promising pipeline of Ironwood Pharmaceuticals, Inc.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
More reports Pharmaceuticals Market Research Reports:
Pharmaceutical Chemicals to 2019
DelveInsight Report, “Chimeric Antigen Receptor (CAR) T cell Immunotherapy- Competitive Landscape, Technology and Pipeline Analysis, 2015” emphasizes on the currently active CAR-T cell products in research and development. The Report covers the 35+ companies which are active in this field including 14 leading companies with 35 products targeting 20 different antigens and 9 different technologies. The Report provides in-depth analysis on the CAR-T cell profiles covering pre-clinical and clinical studies, Collaborations details and Deal values, Technologies and Targeted antigens. The Report provides the CAR-T licensing opportunities, acquisitions, market drivers and barriers followed by SWOT Analysis. Report also describes the unmet needs covered by CAR-T cells highlighting the adverse events, which are major concerns in the market for the usage of CAR-T cells.
Complete report is available at http://www.rnrmarketresearch.com/chimeric-antigen-receptor-car-t-cell-immunotherapy-competitive-landscape-technology-and-pipeline-analysis-2015-market-report.html .
RnR Market Research
Ritesh Tiwari
+ 1 888 391 5441
sales@rnrmarketresearch.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
